Press release
Inflammatory Myositis Market Growth Projections 2024-2034: DelveInsight Analysis | CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharma, Pfizer, Horizon Therapeutics, Eli Lilly
DelveInsight's "Inflammatory Myositis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Inflammatory Myositis, historical and forecasted epidemiology as well as the Inflammatory Myositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Inflammatory Myositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammatory Myositis Market Forecast [https://www.delveinsight.com/sample-request/inflammatory-myositis-im-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Inflammatory Myositis Market Report:
*
The Inflammatory Myositis market size was valued ~USD 589 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In December 2024, argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to enhancing the lives of individuals with severe autoimmune diseases, has announced its decision to advance the development of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA study for adults with idiopathic inflammatory myopathies (IIM or myositis). This decision follows an analysis of topline data from the Phase 2 portion of the trial. The ALKIVIA study will continue enrolling patients across three myositis subtypes: immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM).
*
The market size across the 7MM is expected to grow at a CAGR of approximately 11.7%, driven by heightened disease awareness and the introduction of emerging therapies.
*
In 2023, Germany and Italy held the largest market sizes among EU countries, with USD 69 million and USD 47 million, respectively, while Spain had the smallest market size at USD 21 million.
*
Japan had a market size of USD 72 million in 2023, but this is expected to shift in the coming forecast period.
*
In 2023, there were approximately 188 thousand diagnosed cases of inflammatory myositis across the 7MM, with 92 thousand cases estimated to be from the US. These numbers are expected to rise over the forecast period.
*
The diagnosed prevalent cases of inflammatory myositis were classified into specific types: PM, DM, and IBM, with 76 thousand, 84 thousand, and 27 thousand cases respectively across the 7MM in 2023. These numbers are expected to rise by 2034.
*
In 2023, the age-specific cases of inflammatory myositis in the EU4 and the UK were categorized as follows: 3 thousand cases in individuals aged 0-17 years, 12 thousand in those aged 18-44 years, 25 thousand in the 45-64 age group, and 29 thousand cases in individuals aged 65 years and older.
*
In 2023, the diagnosed prevalent cases of inflammatory myositis in Japan were further categorized by gender, with 10 thousand cases in males and 15 thousand cases in females.
*
Key Inflammatory Myositis Companies: CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others
*
Key Inflammatory Myositis Therapies: Dazukibart (PF-06823859), Hizentra, Efgartigimod, Brepocitinib, Ultomiris, PF-06823859, Daxdilimab, Baricitinib, Nipocalimab, PF-06823859, Froniglutide, Infliximab, Lovaza, Rituximab, and others
*
The Inflammatory Myositis epidemiology based on gender analyzed that females are more susceptible to suffer from Inflammatory myositis when compared to the male population, in the 7MM
*
The Inflammatory Myositis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Myositis pipeline products will significantly revolutionize the Inflammatory Myositis market dynamics.
Inflammatory Myositis Overview
Inflammatory myositis is a group of rare autoimmune disorders characterized by inflammation and weakness of the muscles. These conditions involve inflammation of the muscles (myositis), leading to muscle weakness, pain, and fatigue. There are several types of inflammatory myositis, including polymyositis, dermatomyositis, and inclusion body myositis, each with its own specific features and patterns of muscle involvement.
Get a Free sample for the Inflammatory Myositis Market Report:
https://www.delveinsight.com/report-store/inflammatory-myositis-im-market [https://www.delveinsight.com/report-store/inflammatory-myositis-im-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Inflammatory Myositis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Inflammatory Myositis Epidemiology Segmentation:
The Inflammatory Myositis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Inflammatory Myositis
*
Prevalent Cases of Inflammatory Myositis by severity
*
Gender-specific Prevalence of Inflammatory Myositis
*
Diagnosed Cases of Episodic and Chronic Inflammatory Myositis
Download the report to understand which factors are driving Inflammatory Myositis epidemiology trends @ Inflammatory Myositis Epidemiology Forecast [https://www.delveinsight.com/sample-request/inflammatory-myositis-im-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Inflammatory Myositis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Myositis market or expected to get launched during the study period. The analysis covers Inflammatory Myositis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Inflammatory Myositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Inflammatory Myositis Therapies and Key Companies
*
Dazukibart (PF-06823859): Pfizer
*
Hizentra: CSL Behring
*
Efgartigimod: Argenx
*
Brepocitinib: Priovant Therapeutics/Roivant
*
Ultomiris: Alexion Pharmaceuticals
*
PF-06823859: Pfizer
*
Daxdilimab: Horizon Therapeutics
*
Baricitinib: Eli Lilly and Company
*
Nipocalimab: Janssen Research & Development
*
PF-06823859: Pfizer
*
Froniglutide: Immunoforge Co. Ltd.
*
Infliximab: Schering-Plough
*
Lovaza: GlaxoSmithKline
*
Rituximab: Roche Pharma AG
Discover more about therapies set to grab major Inflammatory Myositis market share @ Inflammatory Myositis Treatment Market [https://www.delveinsight.com/sample-request/inflammatory-myositis-im-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Inflammatory Myositis Market Strengths
*
The therapeutic landscape is prolific in determining the efficacy, safety, and tolerability of novel drugs in patients with IM and its various types.
Inflammatory Myositis Market Opportunities
*
The rising data on overall Inflammatory Myositis prevalence and its subtypes is expected to add significantly to the patient pool.
Scope of the Inflammatory Myositis Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Inflammatory Myositis Companies: CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others
*
Key Inflammatory Myositis Therapies: Dazukibart (PF-06823859), Hizentra, Efgartigimod, Brepocitinib, Ultomiris, PF-06823859, Daxdilimab, Baricitinib, Nipocalimab, PF-06823859, Froniglutide, Infliximab, Lovaza, Rituximab, and others
*
Inflammatory Myositis Therapeutic Assessment: Inflammatory Myositis current marketed and Inflammatory Myositis emerging therapies
*
Inflammatory Myositis Market Dynamics: Inflammatory Myositis market drivers and Inflammatory Myositis market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Inflammatory Myositis Unmet Needs, KOL's views, Analyst's views, Inflammatory Myositis Market Access and Reimbursement
To know more about Inflammatory Myositis companies working in the treatment market, visit @ Inflammatory Myositis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/inflammatory-myositis-im-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Inflammatory Myositis Market Report Introduction
2. Executive Summary for Inflammatory Myositis
3. SWOT analysis of Inflammatory Myositis
4. Inflammatory Myositis Patient Share (%) Overview at a Glance
5. Inflammatory Myositis Market Overview at a Glance
6. Inflammatory Myositis Disease Background and Overview
7. Inflammatory Myositis Epidemiology and Patient Population
8. Country-Specific Patient Population of Inflammatory Myositis
9. Inflammatory Myositis Current Treatment and Medical Practices
10. Inflammatory Myositis Unmet Needs
11. Inflammatory Myositis Emerging Therapies
12. Inflammatory Myositis Market Outlook
13. Country-Wise Inflammatory Myositis Market Analysis (2020-2034)
14. Inflammatory Myositis Market Access and Reimbursement of Therapies
15. Inflammatory Myositis Market Drivers
16. Inflammatory Myositis Market Barriers
17. Inflammatory Myositis Appendix
18. Inflammatory Myositis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=inflammatory-myositis-market-growth-projections-20242034-delveinsight-analysis-csl-behring-argenx-priovant-therapeuticsroivant-alexion-pharma-pfizer-horizon-therapeutics-eli-lilly]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Inflammatory Myositis Market Growth Projections 2024-2034: DelveInsight Analysis | CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharma, Pfizer, Horizon Therapeutics, Eli Lilly here
News-ID: 4137403 • Views: …
More Releases from ABNewswire
Transdermal Growth Support Solutions Gain Traction as Parents Seek Height Manage …
Growth supplement patches like Hautuki are gaining popularity as parents seek pill-free alternatives. The transdermal market is expected to grow 12% annually over five years.
TDDS-Based Products Appeal to Parents Through Enhanced Convenience and Compliance
As parental interest in children's height development continues to surge, transdermal patch-based growth support solutions are emerging as a compelling alternative to traditional oral supplements.
Image: https://www.abnewswire.com/upload/2025/08/6def5abec02881b17cbd81ba7c56c98b.jpg
Child wearing Hautuki [https://hautuki.sg/] growth Support Pach
Search Volume Surge Reflects Growing Demand
Recent…
Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, …
The Key Asthma Companies in the market include - GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Cumberland Pharmaceuticals, Pulmatrix Inc., and others.
DelveInsight's "Asthma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Asthma, historical and forecasted epidemiology as well as the Asthma market trends in the United States,…
Car T Cell Therapy For Multiple Myeloma Market Growth to Accelerate in Forecast …
The Key Car T Cell Therapy For Multiple Myeloma Companies in the market include- Johnson & Johnson (Janssen), Bristol-Myers Squibb, Bluebird bio, Novartis, Nanjing IASO Biotherapeutics, Gadeta, Allogene Therapeutics, Celyad Oncology, Luminary Therapeutics, Caribou Biosciences, Cellectis SA, bluebird bio, Juno Therapeutics, CRISPR Therapeutics, and others.
DelveInsight's "Car T Cell Therapy For Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Car T Cell Therapy For…
LiftmyCV Expands Automated AI Job Search to 10 Platforms
LiftmyCV's AI job search agent now supports Greenhouse, Wellfound and Glassdoor, as the company continues scaling its automation across more than 10 leading job boards and ATS platforms.
London, UK - 7th August, 2025 - LiftmyCV, a fast-growing startup building AI tools for job seekers, has announced a major expansion of its Automated AI Job Search [https://www.liftmycv.com/automated-job-search/] system. With new integrations for Greenhouse, Glassdoor, and Wellfound, the platform now supports full…
More Releases for Inflammatory
Rising Incidence Of Inflammatory Bowel Disease Fuels Growth In The Anti-Inflamma …
The Anti-Inflammatory Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Anti-Inflammatory Therapeutics Market Size and Projected Growth Rate?
The market size of anti-inflammatory therapeutics has shown a consistent growth in the past few years. The market is projected to expand from $114.71…
Rising Incidence Of Inflammatory Bowel Disease Fuels Growth In The Anti-Inflamma …
What market dynamics are playing a key role in accelerating the growth of the anti-inflammatory therapeutics market?
As inflammatory bowel disease becomes more commonplace, it is predicted to encourage progress in the anti-inflammatory therapeutics market. Characterized as a long-term condition causing inflammation of the digestive tract, inflammatory bowel disease (IBD) is effectively managed with the usage of anti-inflammatory therapeutics. These treatments are central in the control of Crohn's disease via decreasing…
Inflammatory Bowel Disease Market: Trends and Outlook
The inflammatory bowel disease (IBD) treatment market is projected to expand from USD 19.91 billion in 2023 to approximately USD 33.19 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.5% between 2024 and 2032.
Download Statistical Data: https://www.towardshealthcare.com/download-statistics/5149
Understanding the Rising Impact of Inflammatory Bowel Disease (IBD) and Advances in Crohn's Disease Research
Inflammatory Bowel Disease (IBD), which includes Crohn's disease and ulcerative colitis, continues to rise globally, posing…
Anti-Inflammatory Activity Enzyme Manufacturer | Pearlzyme Inc
Pearlzyme Inc. is a South Korean company that manufactures anti inflammatory activity enzymes. This anti-inflammatory activity enzyme boosts the animal's immune system against infection and increases milk lactation.
Pearlzyme Inc. is committed to providing high-quality products and services to its customers. The company has a team of experienced scientists and engineers who are constantly working to develop new and innovative products. Pearlzyme Inc. is also committed to sustainable development and is…
Inflammatory Bowel Disease Market: The Present and Future of Inflammatory Bowel …
Stratagem Market Insights have included the latest addition of a global market research report titled Inflammatory Bowel Disease Market tits expansive repository. The report studies primary and secondary research in order to analyze the data effectively. The market study further draws attention to crucial industry factors such as global clients, potential customers, and sellers, which instigates positive company growth. In order to gauge the turning point of the businesses, significant…
Rising incidences of chronic inflammatory and autoimmune diseases has increased …
According to a new report published by apacmarket.com, titled, Anti-inflammatory Therapeutics Asia-Pacific Market Research Report, 2014-2020, the Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR of 8.6% during the period of 2015-2020. The arthritis segment would continue to lead the Asia Pacific anti-inflammatory therapeutics market through 2020. China anti-inflammatory therapeutics market is forecast to grow at the highest CAGR of 13.9% during the forecast period.
Get the sample…
